Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

  • Revenue in EUR (TTM)19.47bn
  • Net income in EUR483.59m
  • Incorporated2006
  • Employees117.13k
More ▼

Institutional shareholders

26.96%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Dec 202319.54m6.66%
Pzena Investment Management LLCas of 24 Oct 202215.25m5.20%
Harris Associates LPas of 26 Oct 202314.74m5.02%
The Vanguard Group, Inc.as of 09 May 20247.38m2.51%
Artisan Partners LPas of 31 Dec 20236.12m2.08%
Barings (UK) Ltd.as of 31 Mar 20234.04m1.38%
BlackRock Fund Advisorsas of 09 May 20243.63m1.24%
FIL Investments Internationalas of 31 Mar 20243.22m1.10%
Norges Bank Investment Managementas of 31 Dec 20232.96m1.01%
Dimensional Fund Advisors LPas of 09 May 20242.23m0.76%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.